Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease

被引：0

作者：

Zaccagna, A

Bertone, A

Puiatti, P

Picciotto, F

Sprujevnik, T

Santucci, R

Rossini, FP

机构：

[1] IRCC, Inst Canc Res & Treatment, Operat Unit Dermatol Surg, I-10060 Candiolo, Italy

[2] Hosp S Giovanni AS, Dept Oncol, Unit Gastroenterol Endoscopy, I-10123 Turin, Italy

来源：

EUROPEAN JOURNAL OF DERMATOLOGY | 2003年 / 13卷 / 03期

关键词：

Crohns disease; infliximab; neutrophilic dermatoses; Pyoderma gangrenosum; therapy; tumor-necrosis-factor-alpha;

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Here we report a case of Pyoderma gangrenosum (PG) associated with Crohn's disease successfully treated with infliximab. The efficacy of this drug in many inflammatory diseases has already been reported, but its use in PG has only been seen in very few cases. Our study confirms that this therapy is a valid alternative solution for treating PG, which is often unresponsive to conventional therapies.

引用

页码：258 / 260

页数：3

共 50 条

[1] Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: A case report
Principi, M
Di Leo, A
Ingrosso, M
Pisani, A
Marangi, S
Amoruso, A
Panella, C
Francavilla, A
Ierardi, E
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2004, 26 (02) : 243 - 248
[2] Treatment of pyoderma gangrenosum with Infliximab in Crohn's disease
Sapienza, MS
Cohen, S
DiMarino, AJ
DIGESTIVE DISEASES AND SCIENCES, 2004, 49 (09) : 1454 - 1457
[3] Treatment of Pyoderma Gangrenosum with Infliximab in Crohn's Disease
Mark S. Sapienza
Sidney Cohen
Anthony J. Dimarino
Digestive Diseases and Sciences, 2004, 49 : 1454 - 1457
[4] Demyelination during anti-tumor necrosis factor α therapy with infliximab for Crohn's disease
Thomas, CW
Weinshenker, BG
Sandborn, WJ
INFLAMMATORY BOWEL DISEASES, 2004, 10 (01) : 28 - 31
[5] The Role of Oxidative Stress in Anti-tumor Necrosis Factor Antibody Treatment in Crohn's Disease
Kupcova, V.
Turecky, L.
Uhlikova, E.
CURRENT MEDICINAL CHEMISTRY, 2012, 19 (30) : 5226 - 5231
[6] Tacrolimus Salvage in Anti-Tumor Necrosis Factor Antibody Treatment-Refractory Crohn's Disease
Gerich, Mark E.
Pardi, Darrell S.
Bruining, David H.
Kammer, Patricia P.
Becker, Brenda D.
Tremaine, William T.
INFLAMMATORY BOWEL DISEASES, 2013, 19 (06) : 1107 - 1111
[7] Certolizumab Pegol: A Polyethylene Glycolated Fab' Fragment of Humanized Anti-Tumor Necrosis Factor Alpha Monoclonal Antibody for the Treatment of Crohn's Disease
Baker, Danial E.
REVIEWS IN GASTROENTEROLOGICAL DISORDERS, 2008, 8 (04) : 240 - 253
[8] Mechanism and Therapeutic Strategy of Secondary Failure to Anti-Tumor Necrosis Factor-α Monoclonal Antibody Treatment for Crohn's Disease
Matsuoka, Katsuyoshi
Kanai, Takanori
DIGESTION, 2013, 88 (01) : 17 - 19
[9] A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease
Papamichael, Konstantinos
Mantzaris, Gerassimos J.
Peyrin-Biroulet, Laurent
EXPERT OPINION ON DRUG SAFETY, 2016, 15 (04) : 493 - 501
[10] Anti-Tumor Necrosis Factor-Alpha (TNF-alpha) Treatment Strategies in Crohn's Disease
Reimund, Jean-Marie
Ratajczyk, Julia
Sola, Brigitte
Justum, Anne-Marie
Muller, Christian D.
RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2007, 1 (01) : 21 - 34

← 1 2 3 4 5 →